Skip to main content
. Author manuscript; available in PMC: 2015 Jul 19.
Published in final edited form as: Cancer Res. 2013 Mar 29;73(10):3051–3061. doi: 10.1158/0008-5472.CAN-12-4136

Table 2.

IC50 values (µmol/L) against various agents

Cell line Chemotherapeutic agent
 HDAC inhibitor
 Proteasome
inhibitor
Bortezomib
CDDP DOC PTX TSA SAHA
HCC827     4.51 0.0021 0.0032 0.082 1.85 0.0044
HCC827-GR-step     4.29 0.0020 0.0020 0.092 0.63 0.0072
HCC827-GR-high1     4.45 0.022a 0.15a 0.097 2.05 0.0061
HCC827-GR-high2     8.04 0.51a 1.46a 0.092 2.20 0.0074
PC-9     2.92 0.00066 0.0014 0.020 1.06 0.0097
PC-9-GR-step     2.49 0.0060 0.0014 0.018 1.14 0.0073
PC-9-GR-high     5.64 0.0020a 0.0022 0.026 1.03 0.017
HCC4006 >10 0.038 0.038 0.55 9.15 0.13
HCC4006-GR-step >10 0.025 0.015 0.13 5.94 0.14
HCC4006-GR-high >10 0.824a 1.10a 2.22 8.20 0.15
HCC4011 >10 0.0011 0.0014 0.021 0.97 0.0033
HCC4011-GR-step >10 0.00069 0.0017 0.017 0.86 0.0061
HCC4011-GR-high >10 0.00034 0.0014 0.018 0.93 0.0055

Abbreviations: CDDP, cisplatin; DOC, docetaxel; PTX, paclitaxel; TSA, trichostatin A.

a

The ratio of the IC50 value in each resistant line to the parental line is higher than 10 times.